Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THRX > SEC Filings for THRX > Form 8-K/A on 6-Mar-2014All Recent SEC Filings

Show all filings for THERAVANCE INC

Form 8-K/A for THERAVANCE INC


6-Mar-2014

Entry into a Material Definitive Agreement, Financial Statements and Exhibits


Item 1.01. Entry into a Material Definitive Agreement.

As previously reported on the Form 8-K filed by Theravance, Inc., a Delaware corporation (the "Company"), on March 3, 2014 (the "Prior Form 8-K"), the Company entered into a Master Agreement (the "Master Agreement") on March 3, 2014 with Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales ("GSK"), and Theravance Biopharma, Inc., a Cayman Islands exempted company and currently a wholly-owned subsidiary of the Company. In connection with the Master Agreement, the Company also entered into a Collaboration Agreement Amendment amending the Collaboration Agreement between the Company and GSK dated as of November 14, 2002, as amended, and a Strategic Alliance Agreement Amendment amending the Strategic Alliance Agreement between the Company and GSK dated as of March 30, 2004, as amended. The agreements referred to in the prior sentence are referred to herein and the Prior Form 8-K as the "Amendments."

The descriptions of the terms and conditions of the Master Agreement and the Amendments in the Prior Form 8-K are qualified in their entirety by reference to the Master Agreement and the Amendments, copies of which are attached as Exhibits 10.1, 10.2 and 10.3 to this Current Report on Form 8-K/A and are incorporated herein by reference.

The information in this Item 1.01 above supplements, but does not replace the information in Item 1.01 of the Prior Form 8-K.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number                               Description

10.1             Master Agreement by and among Theravance, Inc., Theravance
                 Biopharma, Inc. and Glaxo Group Limited, dated March 3, 2014
10.2             Collaboration Agreement Amendment by and between Theravance, Inc.
                 and Glaxo Group Limited dated March 3, 2014*
10.3             Strategic Alliance Agreement Amendment by and between
                 Theravance, Inc. and Glaxo Group Limited dated March 3, 2014*



* Confidential treatment has been requested from the Securities and Exchange Commission as to certain portions of this exhibit.


  Add THRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THRX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.